Patterns of Cancer Genetic Testing: A Randomized Survey of Oregon Clinicians

Table 3

Likelihood that clinicians reported ordering or recommending specific cancer genomic test in the past 12 months, by provider group.

	Total; clinicians	PCPs^b; n (column %)^c; adjusted OR^d; (95%  CI)^e	Naturopaths; n (column %)^c; adjusted OR^d; (95%  CI)^e	OB-GYNs; n (column %)^c; adjusted OR^d; (95%  CI)^e	Specialists^f; n (column %)^c; adjusted OR^d; (95%  CI)^e
BRCA for patients without BC^g or OC^h,i,j	176 (62.6%)	51 (53.7%); 1.0 (referent)	14 (36.8%); 0.8 (0.3–1.9)	75 (77.3%); 2.1 (1.1–4.2)	36 (70.6%); 2.1 (1.0–4.7)^k
BRCA for patients with BC^g or OC^h,i,l	91 (63.6%)	14 (66.7%); 1.0 (referent)	14 (46.7%); 0.5 (0.1–1.7)	11 (64.7%); 0.5 (0.1–2.1)	52 (69.3%); 0.7 (0.2–2.1)
Lynch syndrome testing^m for patients without cancer^n,o	68 (49.6%)	9 (25.0%); 1.0 (referent)	4 (50.0%); 3.9 (0.8–20.6)	10 (50.0%); 2.6 (0.8–8.8)	45 (61.6%); 2.2 (0.7–7.3)
Lynch syndrome testing^m for patients with cancer^n,p	56 (61.5%)	5 (45.5%); 1.0 (referent)	NA^q	NA^q	50 (65.8%); 1.5 (0.4–5.5)

^aBolded estimates indicate significant findings.
^bPCPs: primary care providers include family physicians, internal medicine physicians, primary care nurse practitioners, and primary care physician assistants.
^cThe column % reflects the percent responding within each practice category.
^dOR: odds ratio.
^eCI: confidence interval.
^fSpecialists consisted of surgeons, colorectal surgeons, general surgeons, gastroenterologists, oncologists, and gynecologic oncologists.
^gBC: breast cancer.
^hOC: ovarian cancer.
ⁱAdjusted for number of patients seen per week and confidence in breast and ovarian cancer genetics.
^jAmong clinicians who recommend breast and ovarian screening.
^k𝑃>0.05.
^lAmong clinicians who treat breast and/or ovarian cancer.
^mSpecifically testing for mismatch repair (MMR) genes, which may include testing in MCH1, MSH2, MSH6, and PMS2 genes.
ⁿAdjusted for confidence in knowledge of colorectal cancer genetics.
^oAmong clinicians who recommend colorectal cancer screening.
^pAmong clinicians who treat colorectal cancer.
^qUnable to report estimates due to small cell size.